VANCOUVER, Canada I April 29, 2025 I AbCellera (Nasdaq: ABCL) today announced new data on its PSMA x CD3 T-cell engagers (TCEs), presented as a poster at the ...

MARSEILLE, France I April 29, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today shared new preclinical data for ...

BASEL, Switzerland I April 29, 2025 I Sandoz (SIX:SDZ/OTCQX:SDZNY), the global leader in generic and biosimilar medicines, announced today that it has signed ...

AI-designed oligos with goal of making therapies safer and more effective for patients with rare and common diseases ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...

GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...

NORTHBROOK, IL, USA I April 17, 2025 I Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose ...

BUFFALO, NY, USA I April 17, 2025 I As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of ...

Collaboration combines BigHat's AL/ML-powered Milliner™ platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

Findings demonstrate ATYR2810’s anti-tumor activity and increased survival in a model of glioblastoma multiforme (GBM), a primary form of brain cancer.

TAIPEI, Taiwan I April 29, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through innovative ...